News
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback